# MA Cannabis Control Commission finds 13 cannabis products with inaccurate labeled THC potency

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ma-cannabis-control-commission-finds-13-cannabis-products-with-inaccurate-labeled-thc-potency/
> **Published:** 2026-08-15T12:18:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:56:22-04:00
> **Clinical Summary:** MA regulator found inaccurate THC labeling on cannabis products. Learn why potency testing matters for patient safety and clinical dosing.

---

✦ New

CED Clinical Relevance
#67
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.

PolicySafetyTHCDosingIndustryResearchPain

Why This Matters
Inaccurately labeled THC potency creates significant clinical risks because patients cannot reliably dose cannabis for symptom management or predict psychoactive effects, potentially leading to adverse events or therapeutic failure. Clinicians counseling patients on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) need to inform them that product labels may not reflect actual potency, limiting the ability to provide evidence-based dosing recommendations. Regulatory enforcement of accurate labeling is essential for establishing cannabis as a medication with predictable pharmacokinetics comparable to other pharmaceuticals.

Clinical Summary

The Massachusetts [Cannabis Control Commission](https://cedclinic.com/massachusetts-cannabis-industry-shawn-collins-impact/) identified 13 cannabis products with THC potency levels that did not match their labeled amounts, raising significant concerns about product accuracy and [consumer safety](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) in the regulated market. This finding highlights a critical gap in [quality control](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/) and testing standards that directly affects clinical decision-making, as patients and clinicians rely on accurate labeling to determine appropriate dosing and predict therapeutic or adverse effects. Inaccurate potency labeling can lead to unintended overdosing or therapeutic failure, particularly problematic for patients using cannabis for symptom management or those with dose-sensitive conditions. These discrepancies suggest potential failures in either the testing processes, manufacturing controls, or regulatory oversight that are supposed to protect consumers in licensed markets. Clinicians should be aware that even products from regulated dispensaries may have potency variations that could affect patient outcomes and should counsel patients accordingly. Healthcare providers should encourage patients to document actual effects experienced at labeled doses and report discrepancies to state regulators, while advocating for stricter enforcement of testing and labeling requirements to ensure product consistency.

Clinical Perspective

🏥 Inaccurate THC labeling in Massachusetts cannabis products underscores a critical gap between marketed and actual potency that clinicians should acknowledge when counseling patients about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). Given that patients often rely on labeled potency to estimate dosing and predict effects, labeling errors create real risks for both therapeutic miscalculation and unintended adverse effects, particularly in vulnerable populations such as older adults or those with low [cannabis tolerance](https://cedclinic.com/cannabis-tolerance-behavioral-models/). The discrepancy likely reflects variable testing standards and enforcement inconsistencies across regulated markets, though such issues may be even more pronounced in unregulated sources. Clinicians should assume that patient-reported THC content may not reflect actual exposure and remain vigilant for symptoms that seem disproportionate to stated dose, while also advising patients that purchasing from licensed dispensaries with third-party verification offers some—though imperfect—protection. When discussing cannabis for symptom management, practitioners should frame dosing conversations

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20MA%20Cannabis%20Control%20Commission%20finds%2013%20cannabis%20products%20with%20inaccurate%20labeled%20THC%20potency%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73521)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73521)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20MA%20Cannabis%20Control%20Commission%20finds%2013%20cannabis%20products%20with%20inaccurate%20labeled%20THC%20potency%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73521)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

Related Articles

- [Massachusetts THC Potency Audit Flags 13 Cannabis Flower Products](https://cedclinic.com/massachusetts-cannabis-thc-potency-audit-2026/)

- [Massachusetts Regulators Initiate Audits of Cannabis THC Potency Levels – Hemp Gazette](https://cedclinic.com/cannabis-thc-potency-regulation-ct-bill-update/)

- [Medical Cannabis Commission clears path for cultivator inspections, but advocates warn …](https://cedclinic.com/medical-cannabis-commission-clears-path-for-cultivator-inspections-but-advocates-warn/)

📰 Source: [https://www.newsbreak.com/wwlp-1589982/4829931379208-ma-cannabis-control-commission-finds-13-cannabis-products-with-inaccurate-labeled-thc-potency](https://www.newsbreak.com/wwlp-1589982/4829931379208-ma-cannabis-control-commission-finds-13-cannabis-products-with-inaccurate-labeled-thc-potency)

Further Reading
CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/)
Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/)
CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
